U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT06810609) titled 'Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC' on Jan. 24.
Brief Summary: The hypothesis of the study is that induction immunochemotherapy, followed by surgery or chemoradiation and consolidation Durvalumab immunotherapy, can significantly improve event-free survival in patients with resectable or borderline resectable NSCLC at stage IIIA/B compared to existing treatment methods.
Study Start Date: March 31
Study Type: INTERVENTIONAL
Condition:
Lung Cancer Non-Small Cell Cancer (NSCLC)
Intervention:
PROCEDURE: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or o...